Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
Epistemonikos ID: 616d480899f41e61eef725727e442fe94ff7357b
First added on: Dec 11, 2025